TY - JOUR
T1 - Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
AU - WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group
AU - Vale, Claire
AU - Godolphin, Peter J.
AU - Fisher, David
AU - Horby, Peter
AU - Kosiborod, Mikhail N.
AU - Hochman, Judith S
AU - Webster, Katie
AU - Higgins, Julian P. T.
AU - Althouse, Andrew D.
AU - Berwanger, Otavio
AU - Furtado, Remo H M
AU - Gasparyan, Samvel B.
AU - Haynes, Richard
AU - Koch, Gary G
AU - Landray, Martin
AU - Leifer, Eric
AU - Marshall, John
AU - Murthy, Srinivas
AU - Neal, Matthew D.
AU - Staplin, Natalie
AU - Diaz, Janet
AU - Sterne, Jonathan A C
AU - Shankar-Hari, Manu
PY - 2024/9/6
Y1 - 2024/9/6
N2 - Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been proposed as a potential treatment for 3 adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective 4 effects. To-date published evidence from randomised control trials (RCTs) does not provide evidence 5 of benefit. We aimed to estimate the effect of oral administration of SGLT2i compared with usual care 6 or placebo in adults hospitalised with COVID-19.
AB - Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been proposed as a potential treatment for 3 adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective 4 effects. To-date published evidence from randomised control trials (RCTs) does not provide evidence 5 of benefit. We aimed to estimate the effect of oral administration of SGLT2i compared with usual care 6 or placebo in adults hospitalised with COVID-19.
M3 - Article
SN - 2213-8587
JO - The Lancet Diabetes & Endocrinology
JF - The Lancet Diabetes & Endocrinology
ER -